ANALYSIS OF THE EXPENDITURE OF PHARMACEUTICALS PRESCRIBED FOR THE INDICATION OF FEMALE INFERTILITY IN HUNGARY FOR THE PERIOD 2015-2023
Author(s)
Dalma Pónusz-Kovács, MSc1, Luca F. Kajos, BSc, MSc, PhD2, Tímea Csákvári, MSc, PhD3, Róbert Pónusz, MSc, PhD2, Diána Elmer, BSc, MSc, PhD2, Ákos Várnagy, MD, Ph.D., Habil4, József Bódis, MD, Ph.D., Habil4, Imre Boncz, MSc, PhD, MD2;
1University of Pécs, Doctoral School of Health Sciences, Pécs, Hungary, 2University of Pécs, Faculty of Health Sciences, Institute for Health Insurance, Pécs, Hungary, 3University of Pécs, Faculty of Health Sciences, Institute for Health Insurance, Zalaegerszeg, Hungary, 4University of Pécs, Clinical Centre, Department of Obstetrics and Gynaecology, Pécs, Hungary
1University of Pécs, Doctoral School of Health Sciences, Pécs, Hungary, 2University of Pécs, Faculty of Health Sciences, Institute for Health Insurance, Pécs, Hungary, 3University of Pécs, Faculty of Health Sciences, Institute for Health Insurance, Zalaegerszeg, Hungary, 4University of Pécs, Clinical Centre, Department of Obstetrics and Gynaecology, Pécs, Hungary
OBJECTIVES: 15-20% of couples worldwide affected by infertility. In the treatment of infertility, both in the promotion of natural conception and in in vitro procedures, drug therapy plays a major role. The level of subsidies for pharmaceuticals has changed significantly in Hungary in recent years, with 100% state subsidies for IVF treatment due to the increase in state involvement in 2020.
METHODS: The turnover data of prescriptions for infertility diagnoses was analyzed. The following WHO ICD (revision X.) infertility diagnoses were included in the study: N97.0; N97.1; N97.2; N97.3; N97.4; N97.8; N97.9. The study analyzed the expenditure of pharmaceuticals associated with different infertility diagnoses. Moreover, the market share linked to pharmaceutical products was also evaluated. The study database was provided by the Health Data Warehouse of the National Hospital General Directorate. The examined period covered 2015-2023 years. The expenditures were set in USD (the mean value of 1 USD during the study period= 301.70 HUF).
RESULTS: The total expenditure for infertility-related pharmaceutical utilization was 114,0 million USD in Hungary between 2015 and 2023 (total OOP: 18,8 million USD; public expenditure: 94,8 million USD). The highest market share was represented by N97.9 ICD. Between 2015-2019, the patient co-payment averaged HUF 2,85 million USD per year, which decreased to 1,22 million USD between 2020-2023 (-42.3%). The highest amount of public foundation benefits per 10,000 inhabitants, calculated on the basis of the county average for the period under review, was in Baranya county (77,8 thousand USD).
CONCLUSIONS: The OOP expenditure has decreased in the study period, especially from 2020. From that year onwards, the government took on a greater role by increasing public subsidies for infertility-related pharmaceuticals. Based on the result, the financial burden of Hungarian patients related to infertility has been relieved.
METHODS: The turnover data of prescriptions for infertility diagnoses was analyzed. The following WHO ICD (revision X.) infertility diagnoses were included in the study: N97.0; N97.1; N97.2; N97.3; N97.4; N97.8; N97.9. The study analyzed the expenditure of pharmaceuticals associated with different infertility diagnoses. Moreover, the market share linked to pharmaceutical products was also evaluated. The study database was provided by the Health Data Warehouse of the National Hospital General Directorate. The examined period covered 2015-2023 years. The expenditures were set in USD (the mean value of 1 USD during the study period= 301.70 HUF).
RESULTS: The total expenditure for infertility-related pharmaceutical utilization was 114,0 million USD in Hungary between 2015 and 2023 (total OOP: 18,8 million USD; public expenditure: 94,8 million USD). The highest market share was represented by N97.9 ICD. Between 2015-2019, the patient co-payment averaged HUF 2,85 million USD per year, which decreased to 1,22 million USD between 2020-2023 (-42.3%). The highest amount of public foundation benefits per 10,000 inhabitants, calculated on the basis of the county average for the period under review, was in Baranya county (77,8 thousand USD).
CONCLUSIONS: The OOP expenditure has decreased in the study period, especially from 2020. From that year onwards, the government took on a greater role by increasing public subsidies for infertility-related pharmaceuticals. Based on the result, the financial burden of Hungarian patients related to infertility has been relieved.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
HPR53
Topic
Health Policy & Regulatory
Topic Subcategory
Public Spending & National Health Expenditures, Reimbursement & Access Policy
Disease
SDC: Reproductive & Sexual Health